Results 131 to 140 of about 4,367 (184)

Guselkumab in Inflammatory Bowel Disease: Mechanism, Clinical Efficacy, Safety, and Treatment Positioning. [PDF]

J Clin Med
White L, Sharma E, Limdi J, Din S, Patel K, Honap S.   +5 more
europepmc   +1 more source

Asian Pacific Association of Gastroenterology (APAGE) Clinical Practice Guidelines on the Use of Small Molecules and IL-23 p19 Inhibitors in Ulcerative Colitis and Crohn's Disease. [PDF]

J Gastroenterol Hepatol
Ooi CJ, Ling KL, Limsrivilai J, Wei SC, Mak JWY, Kobayashi T, Dang LM, Leong RW, Lin H, Weng MT, Ong WC, Ahuja V, Aniwan S, Hokari R, Lee WJJ, Leow AH, Leung WK, Lim WC, Makharia G, Matsuoka K, Mustaffa N, Ng SC, Philip M, Pisespongsa P, Ali RAR, Ran ZH, Simadibrata M, Sollano J, Tan M, Viet HD, Wan Ibrahim NR, Wu KC, Ye BD, Hilmi I, Asian Pacific Association of Gastroenterology (APAGE) Inflammatory Bowel Disease Committee and Asian Education Network in IBD (AEN‐IBD).   +34 more
europepmc   +1 more source

Post-Marketing Safety Profile of Mirikizumab: A Multi-Database Pharmacovigilance Study Using FAERS and JADER with IL-23 Inhibitor Class Comparison. [PDF]

Bioengineering (Basel)
Choi JG, Gong EJ, Bang CS, Lee JJ.
europepmc   +1 more source

Corticosteroid-sparing effects of risankizumab versus ustekinumab in patients with moderately to severely active Crohn's disease: post hoc results from the phase 3b SEQUENCE trial. [PDF]

J Crohns Colitis
Raine T, Danese S, Schreiber S, Gao X, Hanauer S, Torres J, Cunneen C, Kligys K, Huang X, Garrison A, Neimark E, Anschutz T, Crowley J, Cross RK.   +13 more
europepmc   +1 more source

Systemic Immune-Inflammation Index and Systemic Inflammation Response Index in Psoriasis: Limited Utility for Monitoring Response to IL-23 Inhibitors. [PDF]

Dermatol Pract Concept
Bardazzi F, Natale A, Maltoni L, Clarizio G, Brunetti T, Cafasso G, Sacchelli L, Loi C, Piraccini BM, Cedirian S.   +9 more
europepmc   +1 more source

Risankizumab versus Deucravacitinib in Adults With Moderate Plaque Psoriasis: 16-Week Results from the Phase 4 IMMpactful Trial. [PDF]

Dermatol Ther (Heidelb)
Magnolo N, Soung J, Frew J, Costanzo A, Ruiz-Santiago H, Eyerich K, Llamas-Velasco M, Bukhalo M, Sivamani RK, Moore A, Wu T, Xie J, Patel M, Ashley D, Kaplan B, Stakias V, Espaillat R, Warren RB.   +17 more
europepmc   +1 more source

Effective Management of Recalcitrant Hailey-Hailey Disease With Risankizumab. [PDF]

Int J Dermatol
Justice J, Della Porta A, Niklinska E, Miller JL.   +3 more
europepmc   +1 more source

Real-World Effectiveness of Risankizumab in Refractory Crohn's Disease: The RISANCROHN Study From the ENEIDA Registry. [PDF]

Aliment Pharmacol Ther
Barreiro-de Acosta M, Zabana Y, Nieto-García L, Poncela M, Aguas M, Martínez-Cuevas C, Argüelles-Arias F, Calvo M, Gargallo-Puyuelo CJ, Zabalza L, Trastoy PV, Boscá-Watts MM, Ceballos D, Pascual CM, Rodríguez-Moranta F, de Castro Parga ML, Suárez P, Camps B, Royo V, Baston-Rey I, de Francisco R, García-Lopez S, Martín-Arranz MD, Bermejo F, Alonso-Abreu I, Gisbert JP, Rivero M, Sicilia B, Nicolás I, Teller M, Díaz ÁP, Ricart E, Algara M, Fradejas P, Robledo P, Madero L, Elorza A, Piqueras M, Garcia-Sepulcre MF, Sesé E, Hernandez-Camba A, Izquierdo S, Trapero AM, Iglesias E, Diz-Lois Palomares MT, Brunet-Mas E, Castro Poceiro J, Busquets D, Manosa M, Pajares R, Ferrer JA, Carpio D, Mesonero F, Bujanda L, Lorente R, Santos J, Flores CM, González-Muñoza C, Martín D, Menacho M, Maroto N, Irabien M, Porto-Silva S, Domènech E, Ferreiro-Iglesias R, ENEIDA Project of GETECCU.   +65 more
europepmc   +1 more source

Risankizumab redefines Crohn's treatment after ustekinumab failure. [PDF]

World J Gastrointest Pharmacol Ther
Omullo FP.
europepmc   +1 more source

Effectiveness, Quality of Life and Durability of Risankizumab in Patients with Moderate-to-Severe Psoriasis: Real-World Evidence from the PRIMMA Study. [PDF]

Dermatol Ther (Heidelb)
Snast I, Valdman-Grinshpoun Y, Bathish N, Matz H, Shclar Y, Murad S, Czarnowicki T, Shavit E, Yang L, Goss S, Maor IP, Halperin A, Blonder SN, Cohen R, Bleterman A, Barak M, Pavlovsky L.   +16 more
europepmc   +1 more source